Therapeutic Expertise
Therapeutic Expertise Built for Predictable Enrollment
Across key therapeutic areas, Sequoia combines experienced investigators, established patient populations, and proven study execution to help sponsors accelerate enrollment and deliver consistent results.
Every therapeutic area benefits from:
- Shared clinical operations
- Standardized quality systems
- Centralized recruitment
- Broad, experienced investigator network
40+
Obesity and type 2 diabetes
studies completed
75-80%
representation across
50k charts
Therapeutic Expertise
Therapeutic Expertise Built for Predictable Enrollment
Supported by experienced PIs, including Dr. Vega
Sequoia’s GLP-1 and metabolic research capabilities combine experienced investigators with access to established and diverse patient populations. Embedded practices, targeted pre-screening, and intentional retention strategies help identify qualified participants earlier and support enrollment throughout the study.
Research experience includes: Obesity (including GLP-1 drug class), type 2 diabetes, and metabolic syndrome.
ACTIVE THERAPEUTIC AREA
Cardiovascular Disease
Supported by experienced PIs, including Dr. Wilt
Sequoia supports cardiovascular studies across a broad range of indications, with experienced investigators and access to diverse patient populations through established clinical practices. Streamlined site activation, centralized operations, and targeted pre-screening help sponsors move efficiently from study start-up through enrollment.
With commercial IRB pathways and dedicated study coordinators, Sequoia can activate cardiovascular protocols more efficiently than large academic medical centers, allowing sponsors to expand their research into emerging indications.
Efficient Protocol Activation
Commercial IRB pathways and streamlined site operations help reduce activation barriers and accelerate study start-up.
50%
representative 15-site US study.
ACTIVE THERAPEUTIC AREA
Nephrology
Supported by experienced PIs, including Dr. Awad
Nearly 50 completed nephrology trials
Sequoia’s nephrology research capabilities combine experienced investigators with established patient access and a track record of up to 50 completed nephrology trials. Our centralized clinical operations and streamlined activation processes support efficient study execution across complex renal indications.
ACTIVE INDICATIONS:
ACTIVE THERAPEUTIC AREA
Cardiovascular Disease
Supported by experienced PIs, including Dr. Fierro
Sequoia’s vaccine program is led by Dr. Fierro, a dedicated full-time vaccine PI with more than 20 years of subspecialty focus and 200+ vaccine trials completed. Our dedicated vaccine infrastructure supports efficient study startup while maintaining the regulatory rigor required for early- and late-phase research.
With more than two decades in vaccine research, Sequoia has developed the operational experience, regulatory infrastructure, and Principal Investigator leadership required to support the vaccine development lifecycle, along with government-funded research through BARDA, NIH, and the Department of Defense.
PBMC + PK
On-site capabilities supporting complex vaccine study protocols and sample processing.
Rapid Start-Up + Strong Enrollment
Proven operational processes support efficient activation and a track record of meeting or exceeding enrollment goals.
What therapeutic areas does Sequoia Clinical Research specialize in?
Sequoia specializes in four core therapeutic areas in clinical research: GLP-1 and metabolic disorders (obesity, type 2 diabetes), cardiovascular disease (hypertension, heart failure, and LP(a)), nephrology, and vaccines. Each program is built around focused physician oversight, relevant patient population access, and a documented history of strong enrollment performance against committed targets.
Does Sequoia run GLP-1 and obesity clinical trials?
Yes. Sequoia's GLP-1 and metabolic program is led by Dr. Vega, who has overseen 40+ obesity and type 2 diabetes studies. Through our Houston sites, Sequoia draws from more than 50,000 active patient charts and a patient population that is 75-80% minority, supporting sponsors seeking diverse metabolic and cardiometabolic trial enrollment.
What makes Sequoia a leading vaccine clinical trial site?
Sequoia has completed 200+ vaccine trials over 20+ years under Dr. Fierro, a dedicated full-time vaccine PI. Vaccine capabilities span Phase 1/First-in-Human through Phase 3 and include government-funded studies with BARDA, NIH, and the Department of Defense, reflecting deep regulatory experience across the vaccine development lifecycle.
How does Sequoia perform in nephrology clinical trial enrollment?
Sequoia's nephrology program, led by Dr. Awad, has completed approximately 100 nephrology trials through the CRC network, now part of the Sequoia Clinical Research platform. In one representative 15-site US study, Sequoia enrolled 50% of the study’s 32 participants. This concentration demonstrates the value of combining focused investigator experience, established patient relationships, and commercial research-site operations in competitive renal disease studies. Active indications include chronic kidney disease, IgA nephropathy, and diabetic kidney disease.
Does Sequoia conduct cardiovascular clinical trials?
Yes. Sequoia operates as a cardiovascular clinical research site across established indications, including hypertension, heart failure, and lipid-lowering research, with LP(a) identified as an emerging target area. The program reflects years of consistent trial execution, existing patient access, and dedicated study coordination across Sequoia's Kansas City and Houston sites, giving sponsors confidence in proven site processes.
How does Sequoia select Principal Investigators for each therapeutic area?
Each Sequoia therapeutic area is led by a subspecialty principal investigator whose clinical practice and research experience are concentrated in that specific disease area. Sequoia does not assign generalist investigators to complex subspecialty protocols. Therefore, sponsors can evaluate the physician behind each protocol, including the investigator’s credentials, patient population, and completed study histories in specific indications.